Literature DB >> 24897964

Ear, nose and throat manifestations of mucocutaneous Leishmaniasis: a literature review.

Francesca Marra1, Maria Celeste Chiappetta, Vincenzo Vincenti.   

Abstract

Leishmaniasis comprises a group of diseases caused by a protozoan parasite belonging to the genus Leishmania and transmitted by the bite of infected female sand flies. Leishmaniasis is endemic in 88 countries and causes significant morbidity and mortality worldwide. Phenomena such as globalization and human migration, as well as the increased volume of international travel have extended its prevalence in developed countries. In addition, the incidence of leishmaniasis as an opportunistic disease has increased in recent years because of the growing number of patients with immune depression secondary to chronic illness, neoplasm, transplant and HIV infection, thereby constituting a public health problem. In humans, there are three possible clinical syndromes of leishmaniasis: cutaneous, mucocutaneous and visceral. Mucocutaneous disease is due to extension of local skin disease into the mucosal tissue via direct extension, bloodstream or lymphatics. Lesions interest mainly the oral and nasal mucosa and occasionally the laryngeal and pharyngeal mucosa. If not recognized and adequately treated, MCL may disfigure the patient because of the chronic local destruction of tissue of the nose, pharynx and palate. Because of the invariable involvement of the areas pertaining otorhinolaryngologists, it is important for ENT specialists and family physicians to have awareness of this condition and its clinical manifestations, particularly in presence of a history positive for travel to endemic areas. If mucocutaneous leishmaniasis is suspected, otorhinolaryngologic examination is very helpful in establishing a correct diagnosis, preventing inappropriate treatment.

Entities:  

Mesh:

Year:  2014        PMID: 24897964

Source DB:  PubMed          Journal:  Acta Biomed        ISSN: 0392-4203


  6 in total

Review 1.  Emerging and re-emerging infectious disease in otorhinolaryngology.

Authors:  F Scasso; G Ferrari; G C DE Vincentiis; A Arosio; S Bottero; M Carretti; A Ciardo; S Cocuzza; A Colombo; B Conti; A Cordone; M DE Ciccio; E Delehaye; L Della Vecchia; I DE Macina; C Dentone; P DI Mauro; R Dorati; R Fazio; A Ferrari; G Ferrea; S Giannantonio; I Genta; M Giuliani; D Lucidi; L Maiolino; G Marini; P Marsella; D Meucci; T Modena; B Montemurri; A Odone; S Palma; M L Panatta; M Piemonte; P Pisani; S Pisani; L Prioglio; A Scorpecci; L Scotto DI Santillo; A Serra; C Signorelli; E Sitzia; M L Tropiano; M Trozzi; F M Tucci; L Vezzosi; B Viaggi
Journal:  Acta Otorhinolaryngol Ital       Date:  2018-04       Impact factor: 2.124

Review 2.  Lip leishmaniasis: a case series with molecular identification and literature review.

Authors:  Iraj Mohammadpour; Mohammad Hossein Motazedian; Farhad Handjani; Gholam Reza Hatam
Journal:  BMC Infect Dis       Date:  2017-01-25       Impact factor: 3.090

3.  Multiparametric analysis of host and parasite elements in new world tegumentary leishmaniasis.

Authors:  Bruna Caroline de Carvalho; Tamires Vital; Jaqueline Osiro; Ciro Martins Gomes; Elza Noronha; Bruno Dallago; Ana de Cássia Rosa; Juliana Lott Carvalho; Luciana Hagström; Mariana Hecht; Nadjar Nitz
Journal:  Front Cell Infect Microbiol       Date:  2022-08-09       Impact factor: 6.073

4.  Imipramine alters the sterol profile in Leishmania amazonensis and increases its sensitivity to miconazole.

Authors:  Valter Viana Andrade-Neto; Thaís Martins Pereira; Marilene do Canto-Cavalheiro; Eduardo Caio Torres-Santos
Journal:  Parasit Vectors       Date:  2016-03-31       Impact factor: 3.876

Review 5.  Mucocutaneous leishmaniasis: case report and literature review of a rare endonasal infection.

Authors:  Abrar Adnan Suqati; Annett Pudszuhn; Veit Maria Hofmann
Journal:  Pan Afr Med J       Date:  2020-08-17

Review 6.  Application of Dendrimers for Treating Parasitic Diseases.

Authors:  Veronica Folliero; Carla Zannella; Annalisa Chianese; Debora Stelitano; Annalisa Ambrosino; Anna De Filippis; Marilena Galdiero; Gianluigi Franci; Massimiliano Galdiero
Journal:  Pharmaceutics       Date:  2021-03-05       Impact factor: 6.321

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.